A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.
A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.
复制标题
DOI：
10.3390/ph6111335
复制
发表时间：
2013-11-01
期刊：
影响因子：
--
通讯作者：
Biedenbach D
中科院分区：
文献类型：
--
作者：
Morrissey I;Hackel M;Badal R;Bouchillon S;Hawser S;Biedenbach D
对抗菌剂耐药性的监测为指导微生物学家和传染病专家了解当地环境中耐药性的控制和传播机制提供了重要信息。持续监测社区和当地医院环境中的抗菌素耐药性模式对于指导有效的经验性治疗至关重要。监测抗菌素耐药性趋势研究(SMART)监测了自2002年以来从全球范围内腹内感染和自2009年以来从尿路感染收集的临床革兰阴性杆菌对抗菌药的体外敏感性模式。分析耐药趋势，特别是碳青霉烯类耐药性和超广谱β-内酰胺酶(ESBL S)的比率。收集了来自腹内感染(n=92,086)和尿路感染(n=24,705)的分离株，并采用临床和实验室标准协会的方法进行了检测。这篇综述介绍了十年来对碳青霉烯类抗生素敏感性和超广谱β-内酰胺酶的研究分析，包括这一时期的主要出版物。在过去十年中，SMART研究已被证明是确定病原菌流行率和抗生素敏感性的宝贵资源，并继续为调节敏感性临界点和临床决策提供证据。
Surveillance of antimicrobial agent resistance provides important information to guide microbiologists and infectious disease specialists understanding of the control and the spread of resistance mechanisms within the local environment. Continued monitoring of antimicrobial resistance patterns in the community and in local hospital environments is essential to guide effective empiric therapy. The Study for Monitoring Antimicrobial Resistance Trends (SMART) has monitored the in vitro susceptibility patterns of clinical Gram-negative bacilli to antimicrobial agents collected worldwide from intra-abdominal infections since 2002 and urinary tract infections since 2009. Resistance trends, with a particular focus on carbapenem resistance and the rate of extended-spectrum β-lactamases (ESBLs), were analyzed. Isolates from intra-abdominal infections (n = 92,086) and urinary-tract infections (n = 24,705) were collected and tested using Clinical and Laboratory Standards Institute methods. This review presents carbapenem susceptibility and ESBL rates over ten years of SMART study analysis, including key publications during this period. The SMART study has proved to be a valuable resource in determining pathogen prevalence and antibiotic susceptibility over the last ten years and continues to provide evidence for regulatory susceptibility breakpoints and clinical decision making.